Acumen Pharmaceuticals Inc
NASDAQ:ABOS
Intrinsic Value
Acumen Pharmaceuticals, Inc. discovers and develops medicines and diagnostics for Alzheimer's disease. [ Read More ]
The intrinsic value of one
ABOS
stock under the Base Case scenario is
4.77
USD.
Compared to the current market price of 3.16 USD,
Acumen Pharmaceuticals Inc
is
Undervalued by 34%.
Acumen Pharmaceuticals Inc's market capitalization is 183m USD.
ABOS stock price is 3.16 USD.
ABOS stock price (3.16 USD) is 34% less than its Intrinsic Value (4.77 USD).
ABOS. Open Relative Valuation
ABOS has upside potential of 313% compared to the average analyst price target.
Open Wall St Estimates
ABOS's ROE (Return on Equity) has significantly increased in the last 3 years from -288% to -23%, and is approaching profitability.
ABOS's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -9 660% to -148%, and is approaching profitability.
ABOS has negative Operating Income for the last twelve months.
ABOS has negative Net Income for the last twelve months.
ABOS's ROE (Return on Equity) for the past 12 months is negative and is equal to -23%.
ABOS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -148%.
ABOS's Altman Z-Score is very low and is equal to 1.4.
ABOS has negative Free Cash Flow for the last twelve months.
ABOS's D/E (Debt to Equity) is very low and is equal to 0.11.
ABOS has negative three-year average ROE (Return on Equity): -56%. The company is not efficient at transforming stockholders' equity into net income.
ABOS has negative three-year average ROIC (Return on Invested Capital): -937%. The company is not efficient at using invested capital to generate operating income.
ABOS's short-term assets (247m USD) exceed its short-term liabilties (13m USD).
ABOS's long-term assets (310m USD) exceed its long-term liabilties (43m USD).
ABOS has negative Net Debt. This means that the company has more cash and short-term investments (244m USD) than debt (30m USD).
ABOS doesn't generate enough operating income (-61m USD) to safely cover interest payments on its debt (169k USD).
Valuation Backtest
Acumen Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
ABOS
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Acumen Pharmaceuticals Inc
Balance Sheet Decomposition
Acumen Pharmaceuticals Inc
| Current Assets | 246.6m |
| Cash & Short-Term Investments | 243.5m |
| Other Current Assets | 3.1m |
| Non-Current Assets | 63.5m |
| Long-Term Investments | 62.6m |
| PP&E | 503k |
| Other Non-Current Assets | 454k |
| Current Liabilities | 13m |
| Accounts Payable | 1.4m |
| Accrued Liabilities | 10.6m |
| Other Current Liabilities | 968k |
| Non-Current Liabilities | 30.2m |
| Long-Term Debt | 29.9m |
| Other Non-Current Liabilities | 284k |
Earnings Waterfall
Acumen Pharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-61.1m
USD
|
|
Operating Income
|
-61.1m
USD
|
|
Other Expenses
|
8.8m
USD
|
|
Net Income
|
-52.4m
USD
|
Free Cash Flow Analysis
Acumen Pharmaceuticals Inc
What is Free Cash Flow?
ABOS Profitability Score
Profitability Due Diligence
Acumen Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Acumen Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ABOS Solvency Score
Solvency Due Diligence
Acumen Pharmaceuticals Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Acumen Pharmaceuticals Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABOS Price Targets Summary
Acumen Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
ABOS
is 13.06 USD
with a low forecast of 10.1 USD and a high forecast of 15.75 USD.
Ownership
ABOS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ABOS Price
Acumen Pharmaceuticals Inc
| Average Annual Return | -44.18% |
| Standard Deviation of Annual Returns | 31.59% |
| Max Drawdown | -91% |
| Market Capitalization | 183m USD |
| Shares Outstanding | 57 910 500 |
| Percentage of Shares Shorted | 2.48% |
Company Profile
Acumen Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Acumen Pharmaceuticals, Inc. discovers and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Charlottesville, Virginia and currently employs 14 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. The firm's ACU193 is a humanized monoclonal antibody that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The firm's therapeutic approach focuses on targeting AbOs, which is a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques.
Contact
IPO
Employees
Officers
The intrinsic value of one
ABOS
stock under the Base Case scenario is
4.77
USD.
Compared to the current market price of 3.16 USD,
Acumen Pharmaceuticals Inc
is
Undervalued by 34%.
You don't have any saved screeners yet
